New drug HDM2020 targets tough lung cancer in early trial
NCT ID NCT07638891
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called HDM2020 in 150 people with advanced squamous non-small cell lung cancer. The drug is designed to target a protein on cancer cells and deliver a chemotherapy agent directly to them. The main goals are to check if the drug is safe and tolerable, and to see if it can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM2020 (a drug that targets FGFR2b and delivers a chemotherapy agent directly to cancer cells)
What this could lead to
If this drug proves safe and effective, it could offer a new treatment option for people with advanced squamous non-small cell lung cancer.
What could go wrong
This is an early Phase 1 trial, so the drug may not work or could have unexpected side effects. Results are preliminary and need confirmation in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NON-SMALL CELL LUNG CANCER(NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••